Company
Amgen
Amgen Inc.
Public (NASDAQ:AMGN) · Thousand Oaks, California, USA · Last verified Aug 15, 2024
Biotechnology company developing maritide (AMG 133), an antibody-peptide conjugate for obesity.
Company profile
- Legal name
- Amgen Inc.
- Status
- public
- Ticker
- NASDAQ:AMGN
- Headquarters
- Thousand Oaks, California, USA
- Website
- www.amgen.com
Active assets
| Asset | Stage | Indications |
|---|---|---|
| Maritide | Phase 1/2 | — |
Trial roll-up
View all →| Registry ID | Phase | Title | Status |
|---|---|---|---|
| NCT03548935 | Phase 1 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 133 in Adult Subjects With Overweight/Obesity | Completed |